Danish biotech firm Dako enters collaboration with Genentech  

Dako enters collaboration with Genentech to seek to expand the market for targeted therapies
Danish biotech firm Dako, a provider of tissue-based cancer diagnostics, has announced in a press release that it has signed a collaborative agreement with Genentech Inc., the internationally known US based biotechnology company, to develop tests which can identify patients who may benefit more from a certain kinds of treatment.

Dako's CEO Patrik Dahlén says in the press release: “We are very pleased to announce our collaboration with Genentech to potentially further expand the market for targeted therapies. We see a great potential in a strong collaborative approach between biotechnology and pharmaceutical companies and diagnostic companies in targeting the right drugs for the right patients, both to improve patient care and more efficiently managing health care costs.”

Founded in 1966 by Danish physician Niels Harboe, Dako is headquartered in Denmark with manufacturing and research sites in Glostrup, Denmark and Carpinteria, California, USA. In 2007, private equity fund EQT V acquired Dako in a DKK 7.25bn (USD 1.2bn) deal.
Link > Dako   

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×